enfortumab vedotin-ejfv for injection
for intravenous use Initial U.S. Approval: 2019
Enfortumab Vedotin-EJFV for Injection is a “used to treat bladder cancer and cancers of the urinary tract“. PADCEV for injection is a “prescription medicine. It is available in “form and strength” For Injection: 20 mg and 30 mg of enfortumab vedotin-ejfv as a lyophilized powder in a single-dose vial for reconstitution. PADCEV for injection can be obtained in India upon request.
To inquire about the “offer price in India”, “shipping process”, and the “estimated time of availability in India”, please get in touch at +91 9891 296 838 (Mr. Tarun) / +91 9811 747 774 (Mr. Neeraj). with the IPN Delhi healthcare team for further discussion.”
Facts about your medicine
Active substance: enfortumab vedotin-ejfv
Disease Indications-Urothelial Carcinoma
Manufacturer-Astellas Pharma Inc.
Usage-1.25 mg/kg intravenous infusion
Medicine Approved By-Food and Drug Administration (FDA)
Summary of FDA-approved use on approval date: Click Here
(see Drugs@FDA for complete indication)